Stockscreener 앱 받기
25.99
4.71%
1.17
시장 영업 전:
24.18
-1.81
-6.96%
Bright Minds Biosciences Inc 주식(DRUG)의 최신 뉴스
What analysts say about Bright Minds Biosciences Inc. stockConsistently superior profits - Jammu Links News
Does Bright Minds Biosciences Inc. stock pay reliable dividendsSmall Risk Large Return Trades - Newser
Can Bright Minds Biosciences Inc. stock recover from recent declineFree Access to Community - Newser
Why Bright Minds Biosciences Inc. stock attracts strong analyst attentionTop Performer Shortlist - Newser
How Bright Minds Biosciences Inc. stock performs during market volatilityFree Trading Group - Newser
What makes Bright Minds Biosciences Inc. stock price move sharplyRisk Controlled Trading Ideas - Newser
Why TBCH stock attracts strong analyst attentionTop Momentum Stock Pick - Newser
How To Trade (DRUG) - news.stocktradersdaily.com
Cantor Fitzgerald Forecasts DRUG FY2025 Earnings - Defense World
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Rating of “Buy” by Analysts - Defense World
4,793 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Acquired by Bank of America Corp DE - Defense World
DRUG FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World
6,600 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Acquired by Jane Street Group LLC - Defense World
40,379 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Purchased by Millennium Management LLC - Defense World
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Buy” from Analysts - Defense World
(DRUG) Investment Analysis and Advice - news.stocktradersdaily.com
Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Bright Minds Showcases Revolutionary CNS Drug Portfolio at Major Jefferies Healthcare Conference - Stock Titan
HC Wainwright Issues Pessimistic Outlook for DRUG Earnings - Defense World
What is Chardan Capital’s Forecast for DRUG FY2025 Earnings? - Defense World
Chardan Capital Reiterates “Buy” Rating for Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Bright Minds Biosciences (DRUG) Receives Consistent 'Buy' Rating from Chardan Capital | DRUG Stock News - GuruFocus
Bright Minds (DRUG) Schedules Virtual R&D Day to Discuss Epileps - GuruFocus
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 - The Manila Times
Top Neurologists Reveal Latest Absence Epilepsy Breakthrough: Bright Minds Showcases Phase 2 Trial Progress - Stock Titan
FY2025 Earnings Forecast for DRUG Issued By Chardan Capital - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded at Cantor Fitzgerald - Defense World
Bright Minds Biosciences (DRUG) to Release Earnings on Wednesday - Defense World
TD Cowen Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation - Nasdaq
Bright Minds stock rating initiated with Buy at TD Cowen - Investing.com Australia
TD Cowen Initiates Coverage on Bright Minds Biosciences (DRUG) w - GuruFocus
Bright Minds stock rating initiated with Buy at TD Cowen By Investing.com - Investing.com Nigeria
Bright Minds Biosciences Says BMB-101 Eliminated Drop Attacks in Mouse Model of Epilepsy - marketscreener.com
Bright Minds (DRUG) Reports Promising Results in Epilepsy Research | DRUG Stock News - GuruFocus
Bright Minds reports BMB-101 eliminates drop attacks in mice By Investing.com - Investing.com Nigeria
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 - The Manila Times
Bright Minds (DRUG) Gains 'Buy' Rating from TD Cowen Analyst | D - GuruFocus
Brokerages Set Bright Minds Biosciences Inc. (NASDAQ:DRUG) Target Price at $83.25 - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Research Coverage Started at Chardan Capital - Defense World
Chardan Capital Initiates a Buy Rating on Bright Minds Biosciences (DRUG) - The Globe and Mail
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside - Benzinga
(DRUG) On The My Stocks Page - news.stocktradersdaily.com
Chardan Capital Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation - Nasdaq
Chardan sets Bright Minds stock Buy rating, $80 target By Investing.com - Investing.com India
Chardan sets Bright Minds stock Buy rating, $80 target - Investing.com
Piper Sandler Reaffirms Their Buy Rating on Bright Minds Biosciences (DRUG) - The Globe and Mail
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study - The Manila Times
0.64%
0.37%
자본화:
|
볼륨(24시간):